Table 2

 CSF levels and ratio of NfH phosphoforms, EDSS, AI, and 9HPT at baseline in patients with MS and OND (controls), and CSF levels and ratio of NfH phosphoforms, EDSS, AI, and 9HPT, and change over time (ΔNfH) at follow up in patients with MS. Values are median (interquartile range)

ONDMultiple sclerosis
AllSP/PPRR
9HPT, nine hole PEG test; AI, ambulation index; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; N/A, not applicable; NfHSMI34, NfH detected with SMI34 antibody; NfHSMI35, NfH detected with SMI35 antibody; OND, other neurological diseases; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.
Baseline
    Number271/119291910
    NfHSMI35 (pg/ml)260 (0–3990)78 (80–610)95 (25–163)53 (11–139)
p<0.001
    NfHSMI34 (pg/ml)10 (0–12000)9 (7–13)11 (7–14)7 (5–9)
p<0.05
    Ratio1.52 (0.36–5.49)1.5 (0.6–5.4)1.7 (0.6–5.8)1 (0.42–3.5)
    EDSSN/A3.25 (2.0–6.5)6.0 (3.0–7.0)1.5 (1.0–2.0)
p<0.001
    AIN/A2 (1–7)6 (2–8)1 (1–1)
p<0.01
    9HPTN/A24.5 (20.5–28.5)26.0 (24.0–30.0)20.0 (18.0–22.0)
p<0.01
Follow up
    Number291910
    NfHSMI35 (pg/ml)N/A113 (0–178)129 (0–209)0 (0–120)
p<0.05
    NfHSMI34 (pg/ml)N/A50 (9–129)30 (10–114)51 (3–120)
    RatioN/A3 (1–10.1)3 (1–10.1)5 (0–10)
    ΔNfHSMI35 (pg/ml)N/A4 (−59–98)82 (−38–115)−49 (−38–104)
    ΔNfHSMI34 (pg/ml)N/A37 (−1–123)22 (−3–95)51 (1–112)
    EDSSN/A4.5 (3.5–6.0)5.5 (4.0–6.5)3.0 (2.5–4.0)
p<0.01
    AIN/A2 (2–5)4 (2–7)1 (1–2)
p<0.01
    9HPTN/A23.5 (20.0–28.5)24.5 (21.5–31.0)20.0 (18.0–21.0)
p<0.05